Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases

Hirotsugu Uemura,Hiroji Uemura,Satsohi Nagamori,Yoshiaki Wakumoto,Go Kimura,Hiroaki Kikukawa,Akira Yokomizo,Atsushi Mizokami,Takeo Kosaka,Naoya Masumori,Yoshihide Kawasaki,Junji Yonese,Yasutomo Nasu,Satoshi Fukasawa,Takayuki Sugiyama,Seigo Kinuya,Makoto Hosono,Iku Yamaguchi,Takashi Akagawa,Nobuaki Matsubara

Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases

2019

Background Radium-223 is a first-in-class targeted alpha therapy to prolong overall survival (OS) in castration-resistant prostate cancer with bone metastases (mCRPC). The aim of the present analysis was to assess the long-term safety with radium-223 in Japanese patients with mCRPC.

Keywords:

Oncology
Phases of clinical research
Castration
General surgery
Radium-223 Dichloride
Prostate cancer
Internal medicine
Medicine
Leukemia
Malignancy
Aplastic anemia
Gastroenterology
Anemia
Adverse effect
Cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations